InflaRx Announces 2026 AGM and Proposed Director Re-appointments

InflaRx N.V. has filed a Form 6-K to convene its 2026 Annual General Meeting (AGM) of shareholders, scheduled for April 23, 2026. Key agenda items include the re-appointment of several directors to terms ending in 2030, including executive directors Prof. Niels Riedemann (CEO) and Prof. Renfeng Guo (CSO), and non-executive directors Nicolas Fulpius, Richard Brudnick, and Hege Hellstrom. The Board is also seeking shareholder approval for several financial and corporate governance matters: the adoption of the 2025 statutory annual accounts, the extension of authorizations to issue shares and exclude pre-emption rights for five years, and the extension of authorization to acquire company shares for 18 months. Notably, the Board proposes an amendment to the Articles of Association to increase the authorized share capital and the approval of a new Long-term Incentive Plan (LTIP 2026). The LTIP 2026 would increase the maximum annual share issuance limit to 6.5% of outstanding shares, up from the current 4% under the 2017 plan.